{
  "id": 423358,
  "title": "Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?",
  "url": "https://urgent.news/2026/08/10/can-molbio-diagnostics-ipo-deliver-long-term-growth-for-high-risk",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-10T00:26:27.000Z",
  "source": {
    "name": "The Economic Times - Top News",
    "slug": "the-economic-times-top-news",
    "url": "https://economictimes.indiatimes.com/markets/ipos/fpos/can-molbio-diagnostics-ipo-deliver-long-term-growth-for-high-risk-investors/articleshow/133076987.cms"
  },
  "original_language": "en",
  "account": "Molbio Diagnostics, a molecular diagnostics company founded in 2000, is set to launch an IPO to raise capital for expansion. The company plans to issue ₹200 crore through a fresh issue and ₹740 crore via an offer for sale, reducing its promoter group's stake to 43% from 46.6%. Molbio operates six manufacturing facilities across India and serves clients in over 90 countries, with nearly 74% of its revenue coming from the sale of test kits, with a significant portion attributed to Tuberculosis diagnostics.\n\nThe company's success is heavily concentrated among its top clients, which account for over half of its revenue. Given this high customer concentration, the IPO may appeal to investors with a high-risk tolerance, looking for long-term growth potential. Molbio's Truenat platform, a portable diagnostics system for resource-limited settings, offers accurate test results within an hour and provides molecular testing solutions for over 30 diseases through 43 diagnostic assays.\n\nFinancially, Molbio has shown impressive growth, with revenue from operations increasing by 31.5% annually to ₹1,445.7 crore and net profit growing by 40.2% annually to ₹164.1 crore between FY24 and FY26. Ebitda also rose by 33.2% to ₹328.2 crore during the same period, with an Ebitda margin of 22.6% in FY26. Despite having no direct listed peers in India, Molbio's valuation suggests a price-earnings (P/E) multiple of up to 57, placing it within the range of 54 to 81 observed in other healthcare diagnostics and medical device companies.",
  "summary": "Molbio Diagnostics, a molecular diagnostics manufacturer founded in 2000, is set to raise ₹200 crore through a fresh issue and an additional ₹740 crore through an offer for sale to fund capital expenditure. The company operates six manufacturing facilities across India and serves customers in over 90 countries, with nearly 74% of its revenue coming from the sale of test kits, predominantly for Tuberculosis. With a strong focus on research, development, and manufacturing of diagnostic solutions for infectious and non-communicable diseases, Molbio's top clients contribute over half of its revenue, indicating a customer concentration risk. The company's Truenat platform, a portable diagnostics system for resource-limited settings, offers accurate test results within an hour, serving a wide range of diseases through 43 diagnostic assays. Despite the high-risk nature of investing in an IPO at this stage, the company's robust financial performance, with revenue from operations rising 31.5% annually and net profit growing 40.2% annually over the past two fiscal years, suggests potential for long-term growth for high-risk investors.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}